Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness

Nitta,Hidetoshi; Murakami,Yoji; Wada,Yoshihiro; Eto,Masatoshi; Baba,Hideo; Imamura,Takahisa

doi:10.3892/or.2014.3341

Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness

Authors:
- Hidetoshi Nitta
- Yoji Murakami
- Yoshihiro Wada
- Masatoshi Eto
- Hideo Baba
- Takahisa Imamura
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan, Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan, Department of Molecular Pathology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan
Published online on: July 18, 2014 https://doi.org/10.3892/or.2014.3341
Pages: 1715-1719

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaphylatoxin C5a indirectly fosters cancer cells through recruitment of myeloid-derived suppressor cells (MDS) for inhibiting antitumor CD8+ T cells and induction of neovascularization. We recently found activation of cancer cells by C5a directly via the C5a-receptor (C5aR; CD88) to enhance invasiveness. Thus, C5a possibly contributes to cancer progression rather than elimination. C5a generation in cancer tissues has been reported; however, the mechanism is not fully elucidated. Cancer cell expression of complement regulatory molecules suggests inefficient C5a generation through activation of the complement system in response to cancer cells. To explore another C5a generation mechanism in cancer tissues, we examined cancer cells for C5a-releasing activity from C5. C5a was present in C5-supplemented culture media of cancer cells including C5aR-expressing cells, and the media enhanced C5aR-expressing cancer cell invasion, which was abolished by anti-C5a antibody. The C5a-releasing activity was absent in the supernatants of the media and was inhibited by aprotinin, a serine protease inhibitor, and decanoyl-Arg-Val-Lys-Arg-chloromethylketone but not by inhibitors specific for cysteine, acid, or metal proteases. These results indicated C5a release from C5 by a cancer cell membrane-bound serine protease that can cleave peptide bonds at the carboxy-terminal site of paired basic amino acid residues. Cancer cell C5a release from the complement-immobilized plasma supported feasibility of this cancer cell protease-dependent C5a generation in cancer tissues. The new mechanism of C5a generation suggests self-activation of C5aR-expressing cancer cells to enhance invasiveness and induction of MDS recruitment and neovascularization to create a microenvironment favorable for cancer progression.

View Figures

View References

1	Ricklin D, Hajishengallis G, Yang K and Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 11:785–797. 2010. View Article : Google Scholar : PubMed/NCBI
2	Niculescu F, Rus HG, Retegan M and Vlaicu R: Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 140:1039–1043. 1992.PubMed/NCBI
3	Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE and Meri S: Ascitic complement system in ovarian cancer. Br J Cancer. 92:895–905. 2005.
4	Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G and Lambris JD: Modulation of the antitumor immune response by complement. Nat Immunol. 9:1225–1235. 2008. View Article : Google Scholar : PubMed/NCBI
5	Corrales L, Ajona D, Rafail S, et al: Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 189:4674–4683. 2012. View Article : Google Scholar : PubMed/NCBI
6	Müller-Eberhard HJ: Molecular organization and function of the complement system. Annu Rev Biochem. 57:321–347. 1988.
7	Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M and Imai Y: Protection of thyroid cancer cells by complementregulatory factors. Cancer. 73:2808–2817. 1994. View Article : Google Scholar : PubMed/NCBI
8	Niehans GA, Cherwitz DL, Staley NA, Knapp DJ and Dalmasso AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. 149:129–142. 1996.
9	Jurians K, Ziegler S, Garcia-Schüller H, Kraus S, Bohana-Kashtan O, Fishelson Z and Kirschfink M: Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 36:929–939. 1999. View Article : Google Scholar : PubMed/NCBI
10	Morgan J, Spendlove I and Durrant L: The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens. 60:213–223. 2002. View Article : Google Scholar : PubMed/NCBI
11	Gancz D and Fishelson Z: Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol. 46:2794–2800. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD and Song WC: The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med. 201:567–577. 2005. View Article : Google Scholar : PubMed/NCBI
13	Mikesch JH, Buerger H, Simon R and Brandt B: Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta. 1766:42–52. 2006.PubMed/NCBI
14	Guo RF and Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol. 23:821–852. 2005. View Article : Google Scholar : PubMed/NCBI
15	Markiewski MM and Lambris JD: The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 171:715–727. 2007. View Article : Google Scholar : PubMed/NCBI
16	Nozaki M, Raisler BJ, Sakurai E, et al: Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA. 103:2328–2333. 2006. View Article : Google Scholar : PubMed/NCBI
17	Gerard NP and Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature. 349:614–617. 1991. View Article : Google Scholar : PubMed/NCBI
18	Nitta H, Wada Y, Kawano Y, et al: Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 19:2004–2013. 2013. View Article : Google Scholar : PubMed/NCBI
19	Huber-Lang M, Sarma JV, Zetoune FS, et al: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 12:682–687. 2006. View Article : Google Scholar : PubMed/NCBI
20	Nitta H, Imamura T, Wada Y, Irie A, Kobayashi H, Okamoto K and Baba H: Production of C5a by ASP, a serine protease released from Aeromonas sobria. J Immunol. 181:3602–3608. 2008. View Article : Google Scholar : PubMed/NCBI
21	Huber-Lang M, Younkin EM, Sarma JV, et al: Generation of C5a by phagocytic cells. Am J Pathol. 161:1849–1859. 2002. View Article : Google Scholar : PubMed/NCBI
22	Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:3239–3245. 1987.PubMed/NCBI
23	Kobayashi H, Utsunomiya H, Yamanaka H, Sei Y, Katunuma N, Okamoto K and Tsuge H: Structural basis for the kexin-like serine protease from Aeromonas sobria as sepsis-causing factor. J Biol Chem. 284:27655–27663. 2009. View Article : Google Scholar : PubMed/NCBI
24	Nitta H, Kobayashi H, Irie A, Baba H, Okamoto K and Imamura T: Activation of prothrombin by ASP, a serine protease released from Aeromonas sobria. FEBS Lett. 581:5935–5939. 2007. View Article : Google Scholar : PubMed/NCBI
25	Tian S and Jianhua W: Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int J Biol Sci. 6:89–95. 2010. View Article : Google Scholar
26	Pintigny D and Dachary-Prigent J: Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and enzymatic study. Eur J Biochem. 207:89–95. 1992. View Article : Google Scholar : PubMed/NCBI
27	Maeda H, Fang J, Inutsuka T and Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 3:319–328. 2003. View Article : Google Scholar : PubMed/NCBI
28	Angliker H, Wilkstrom P, Shaw E, Brenner C and Fuller RS: The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J. 293:75–81. 1993.PubMed/NCBI
29	DiScipio RG, Smith CA, Müller-Eberhard HJ and Hugli TE: The activation of human complement C5 by a fluid phase C5 convertase. J Biol Chem. 258:10629–10636. 1983.PubMed/NCBI
30	Antonini E, Ascenzi P, Bolognesi M, Gatti G, Guameri M and Menegatti E: Interaction between serine (pro)enzymes, and Kazal and Kunitz inhibitors. J Mol Biol. 165:543–558. 1983. View Article : Google Scholar : PubMed/NCBI
31	Angliker H: Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem. 38:4014–4018. 1995. View Article : Google Scholar : PubMed/NCBI
32	Szabo R and Bugge TH: Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 27:213–235. 2011. View Article : Google Scholar : PubMed/NCBI
33	Condeelis J and Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
34	van der Bij GJ, Oosterling SJ, Meijer S, Beelen RH and van Egmond M: The role of macrophages in tumor development. Cell Oncol. 27:203–213. 2005.PubMed/NCBI
35	Crowther M, Brown NJ, Bishop ET and Lewis CE: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 70:478–490. 2001.PubMed/NCBI
36	Nozawa H, Chiu C and Hanahan D: Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA. 103:12493–12498. 2006. View Article : Google Scholar : PubMed/NCBI